The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma
Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, briefly discusses results from the randomized Phase III DREAMM-3 trial (NCT04162210), which compared the safety of belantamab mafodotin monotherapy versus pomalidomide plus dexamethasone (pom/dex) in patients with relapsed/refractory multiple myeloma (R/R MM). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
